-
Azilsartan medoxomil monopotassium Workflow
2026-09-29
Build reproducible AT1-receptor assays and translational hypertension models with a compound selected for sustained receptor engagement. This guide combines practical dosing, plate-based workflow design, comparative benchmarking, and troubleshooting for TAK 491 studies.
-
MG-132 and Proteostasis: Designing Better Assays
2026-09-29
MG-132 and its synonym Z-LLL-al can reveal how proteasome stress reshapes protein stability, apoptosis, and cell-cycle behavior. This article connects MG-132 assay design with mechanistic lessons from a recent ZBTB24–ICF2 study while defining the limits of cross-domain interpretation.
-
Angiotensin I Workflows for ACE and RAS Research
2026-09-28
Use Angiotensin I as a defined substrate to separate ACE conversion from downstream Ang II receptor signaling in cardiovascular, neuroendocrine, and antihypertensive drug studies. This workflow also explains why recent peptide-binding data support matched angiotensin peptide panels rather than treating Angiotensin I as a direct receptor agonist.
-
Angiotensin I: Assay Design Beyond the Pathway
2026-09-28
Angiotensin I is more than a renin–angiotensin system intermediate: it is a substrate whose conversion and measurement must be distinguished carefully. This article connects peptide assay design with lessons from fluorescence-interference research to support more reliable cardiovascular experiments.
-
Angiotensin 1/2 (1-6): From RAS to Assay Design
2026-09-27
Angiotensin 1/2 (1-6), the Asp-Arg-Val-Tyr-Ile-His hexapeptide, is useful for examining both angiotensin processing and an emerging spike–AXL binding observation. This article separates established renin-angiotensin system biology from in-vitro findings and translates that distinction into practical assay-design decisions.
-
CSBTA Pharmacokinetics in MASH Model Mice
2026-09-26
This study integrates plasma, tissue, and cellular measurements to show that HFHCD-associated disease changes the disposition of three Corydalis saxicola Bunting alkaloids, with repeated dosing further increasing exposure, especially for dehydrocavidine. Its transporter and metabolism experiments connect these changes to CYP450 enzymes, Oatp1b2, P-glycoprotein, and PXR, highlighting disease state as a potential source of pharmacokinetic variability in MASLD/MASH research.
-
Sulfaphenazole Restores Vasodilation in Diabetic Mice
2026-09-25
In db/db mice, eight weeks of sulfaphenazole treatment restored acetylcholine-dependent vascular relaxation and improved markers of oxidative stress and nitric oxide availability without changing plasma glucose. The study provides pharmacological evidence that CYP2C-related oxidant production contributes to diabetic endothelial dysfunction, while leaving the responsible isoform and the relevance to human disease open for further testing.
-
Lisinopril dihydrate in ACE inhibition research
2026-09-25
Use lisinopril dihydrate to probe ACE-dependent signaling in cardiovascular and renal models, with a nanomolar potency benchmark and a fresh-solution workflow. Pair ACE readouts with carefully chosen peptidase controls to distinguish target engagement from downstream peptide-processing effects.
-
Angiotensin Peptides and SARS-CoV-2 Receptor Binding
2026-09-24
Oliveira and colleagues report that several naturally occurring angiotensin peptides increase SARS-CoV-2 spike-protein binding to host receptors in antibody-based assays, with the strongest reported effect for angiotensin IV. The results connect renin–angiotensin peptides with a measurable viral-binding phenomenon, but do not establish that these peptides increase infection or disease severity in vivo.
-
Lisinopril Dihydrate in ACE Inhibitor Research
2026-09-24
Use Lisinopril dihydrate to probe ACE inhibition across hypertension, cardiac, and renal research—while keeping enzyme-level activity distinct from whole-model outcomes. A classic peptidase-selectivity study offers a practical framework for choosing controls and testing, rather than assuming, off-target effects.
-
Nonivamide Workflows for TRPV1 and Cancer Research
2026-09-23
Use Nonivamide to activate TRPV1 in controlled cell assays, investigate apoptosis in cancer models, or test chemical stimulation in neuroimmune workflows. This guide separates reported findings from practical starting conditions and shows how to optimize dosing, vehicle controls, and readouts.
-
HBsAg, TBK1, and Autophagy in HBV Immune Evasion
2026-09-23
The reference study identifies a mechanistic link between hepatitis B surface antigen, TBK1 signaling, impaired type I interferon production, and incomplete autophagy. Its evidence suggests that HBsAg redirects TBK1 activity away from IRF3-dependent antiviral signaling while promoting p62 phosphorylation and blocking autophagosome–lysosome fusion, creating conditions that may favor persistent HBV infection.
-
CD80 mRNA: From Costimulation to Translation
2026-09-22
A translational framework for using transient CD80 mRNA expression to dissect T-cell costimulation, validate mechanism, and assess the limits of preclinical immunotherapy evidence.
-
Carvedilol for Reliable Cell Assay Design
2026-09-22
Learn how Carvedilol (SKU B1332) can improve experimental planning for β-adrenergic signaling, oxidative stress, vascular smooth muscle proliferation, and translational hematopoietic studies. This scenario-based guide emphasizes solvent control, concentration selection, assay interpretation, and practical product evaluation.
-
Clarithromycin as a CYP3A Assay Control
2026-09-21
Clarithromycin is a powerful CYP3A inhibitor for pathway-resolved drug-drug interaction research. This article shows how to use it not merely as an inhibitor, but as a mechanistic control that distinguishes CYP3A effects from CYP-independent pharmacokinetics.